The FDA has accepted the biologics license application of datopotamab deruxtecan for the treatment of nonsquamous non-small cell lung cancer.
The BLA for Dato-DXd, a TROP2-directed ADC, in previously treated, advanced, nonsquamous NSCLC has been accepted by the FDA, and a PDUFA target action date is anticipated in the fourth quarter of 2024.1
The application is supported by findings from the phase 3 TROPION-Lung01 trial. Dato-DXd demonstrated superior progression-free survival (PFS) compared with the current standard-of-care treatment docetaxel. Interim results also favor Dato-DXd over docetaxel for overall survival (OS), but the numbers are not yet at statistical significance.
“The take home here was that Dato-DXd was a better tolerated drug from a global perspective, although there are some clear differences in terms of toxicity profile. It appears to be a potential new, meaningful therapy for patients with non-squamous metastatic advanced non-small cell lung cancer eligible for second-line chemotherapy,” said Aaron Lisberg, MD, thoracic medical oncologist at the University of California, Los Angeles, said in an interview with Targeted OncologyTM.
“Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy. With regulatory discussions ongoing around the world and a parallel submission underway in the [United States] in breast cancer, this is only the beginning of our efforts to make this novel treatment available to patients as quickly as possible,” said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca, in a press release.1
Lisberg presented findings from TROPION-Lung01 at the 2023 European Society of Medical Oncology Congress. The median PFS, which was a dual primary end point of the study, was 4.4 months (95% CI, 4.2-5.6) with Dato-DXd vs 3.7 months with docetaxel (HR, 0.75; 95% CI, 0.62-0.91; P =.004).2
The overall response rate (ORR) with Dato-DXd was 26.4% (95% CI, 21.5%-31.8%) vs 12.8% (95% CI, 9.3%-17.1%) with docetaxel. The median duration of response with Dato-DXd was 7.1 months (95% CI, 5.6-10.9) compared with 5.6 months (95% CI, 5.4-8.1) with docetaxel.
Specially for patients with nonsquamous histology, the median PFS was 5.6 months (95% CI, 4.4-7.0) in the Dato-DXd arm vs 3.7 months (95% CI, 2.9-4.2) in the docetaxel arm (HR, 0.63; 95% CI, 0.51-0.78), the ORR was 31.2% vs 12.8%, and the DOR was 7.7 months vs 5.6 months, respectively.
At the interim analysis, the median OS was 12.4 months (95% CI, 10.8-14.8) with Dato-DXd vs 11.0 months (95% CI, 9.8-12.5) with docetaxel (HR, 0.90; 95% CI, 0.72-1.13) among the entire intent-to-treat population. The HR was 0.77 (95% CI, 0.59-1.01) for patients with nonsquamous histology.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More